Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Bristol-Myers Squibb Company ( BMY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.4%. By the end of trading, Bristol-Myers Squibb Company fell $0.63 (-1.2%) to $53.68 on average volume. Throughout the day, 7,200,595 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8,484,200 shares. The stock ranged in price between $53.63-$54.53 after having opened the day at $54.33 as compared to the previous trading day's close of $54.31. Other companies within the Drugs industry that declined today were: Aoxing Pharmaceutical Company ( AXN), down 16.0%, Vivus ( VVUS), down 13.2%, Star Scientific ( STSI), down 8.8% and Advaxis Incorporated ( ADXS), down 6.5%.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $89.3 billion and is part of the health care sector. Shares are up 2.2% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, InterMune ( ITMN), up 170.8%, DARA Biosciences ( DARA), up 23.1%, Genocea Biosciences ( GNCA), up 21.1% and Sunesis Pharmaceuticals ( SNSS), up 17.5% , were all gainers within the drugs industry with Novo Nordisk A/S ( NVO) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact